2022
Cost‐effectiveness of second‐line therapies in adults with chronic immune thrombocytopenia
Goshua G, Sinha P, Kunst N, Pischel L, Lee AI, Cuker A. Cost‐effectiveness of second‐line therapies in adults with chronic immune thrombocytopenia. American Journal Of Hematology 2022, 98: 122-130. PMID: 35147241, PMCID: PMC9365880, DOI: 10.1002/ajh.26497.Peer-Reviewed Original ResearchMeSH KeywordsAdultCost-Benefit AnalysisHumansProspective StudiesPurpura, Thrombocytopenic, IdiopathicRituximabSplenectomyThrombopoietinConceptsThrombopoietin receptor agonistsChronic immune thrombocytopeniaSecond-line therapyImmune thrombocytopeniaEarly useCurrent practice trendsProbabilistic sensitivity analysesCost-effective treatmentFirst cost-effectiveness analysisCost-effectiveness analysisU.S. health systemLack of evidenceEarly splenectomyHematology (ASH) guidelinesReceptor agonistCurrent guidelinesSplenectomyClinical practicePractice trendsTherapyHealth systemCost-effective strategyRituximabThrombocytopeniaAmerican Society
2021
Cost-effectiveness of Tocilizumab in Severe Coronavirus Disease 2019: to See or Not to See
Pischel L, Goshua G. Cost-effectiveness of Tocilizumab in Severe Coronavirus Disease 2019: to See or Not to See. Clinical Infectious Diseases 2021, 73: 2119-2120. PMID: 33999992, PMCID: PMC8194546, DOI: 10.1093/cid/ciab459.Commentaries, Editorials and Letters